Xponance Inc. Purchases 137 Shares of Humana Inc. (NYSE:HUM)

Xponance Inc. increased its position in shares of Humana Inc. (NYSE:HUM) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,649 shares of the insurance provider’s stock after acquiring an additional 137 shares during the quarter. Xponance Inc.’s holdings in Humana were worth $4,478,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HUM. FPC Investment Advisory Inc. purchased a new position in Humana in the fourth quarter worth $27,000. Centricity Wealth Management LLC purchased a new position in Humana during the 4th quarter worth $30,000. LFA Lugano Financial Advisors SA increased its position in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares in the last quarter. OFI Invest Asset Management purchased a new stake in Humana in the fourth quarter valued at about $33,000. Finally, Atwood & Palmer Inc. boosted its holdings in Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after acquiring an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Buying and Selling at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.37% of the company’s stock.

Humana Trading Down 0.3 %

HUM stock opened at $266.62 on Friday. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market cap of $32.18 billion, a P/E ratio of 26.80, a PEG ratio of 2.05 and a beta of 0.57. The company’s 50-day simple moving average is $271.39 and its 200-day simple moving average is $278.13.

Humana (NYSE:HUM) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio is presently 35.58%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HUM shares. Piper Sandler upped their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. StockNews.com lowered shares of Humana from a “buy” rating to a “hold” rating in a research note on Tuesday. Morgan Stanley decreased their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. JPMorgan Chase & Co. dropped their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Nineteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.